A Dramatic Shift in Federal Vaccine Policy

The Trump administration dropped a bombshell on Monday, announcing a massive overhaul of the federal childhood vaccine schedule. And when we say massive, we mean it—the number of recommended vaccines has been slashed from 72 to just 11 core immunizations targeting the most serious diseases.

President Donald Trump took to Truth Social to announce the change, emphasizing that while the required list has shrunk considerably, parents who want the full slate of vaccines can still opt in. The key word here is "opt"—the administration is shifting from a comprehensive recommendation approach to one that focuses on what it considers essential, leaving other decisions in the hands of families and their doctors.

According to the Department of Health and Human Services (HHS), the United States had become an "outlier" compared to other countries, both in the sheer number of childhood vaccines administered and the total doses recommended. The agency says this revision is designed to rebuild public trust by zeroing in on only the most critical vaccinations.

What's Off The Core List

The Centers for Disease Control and Prevention (CDC) has removed routine recommendations for several childhood immunizations that were previously standard. Gone from the core schedule are vaccines for rotavirus, COVID-19, influenza, meningococcal disease, and hepatitis A and B. These shots haven't disappeared—they're just no longer universally recommended, with decisions now left to parents in consultation with healthcare providers.

Importantly, the administration stressed that no families will lose vaccine access or insurance coverage due to this change. The vaccines are still available; they're just not being pushed as aggressively by federal health authorities.

This overhaul represents the latest major policy shift under Health Secretary Robert F. Kennedy Jr., who has a well-documented history of vaccine skepticism and has been driving the administration's approach to immunization policy.

Vaccine Makers Sound The Alarm

This isn't sitting well with pharmaceutical companies that produce these vaccines. Merck & Co. Inc. (MRK) and GSK plc (GSK) are among the major vaccine makers potentially impacted by this policy shift.

The companies already voiced concerns back in December when a U.S. advisory panel decided to remove the long-standing recommendation for a birth-dose hepatitis B vaccine. Merck, which makes Recombivax HB, warned that dropping this recommendation could put infants at serious risk of chronic infection, liver cancer, and even death. GSK, the maker of Engerix-B, emphasized its confidence in the science supporting its vaccine and said it's waiting for the CDC's formal adoption to fully evaluate the impact.

Broader Scrutiny on Vaccine Safety

The timing of this policy change is notable. It comes during a period of heightened scrutiny around vaccine safety and efficacy. The FDA's top vaccine regulator, Vinay Prasad, recently proposed stricter approval rules for vaccines, citing alleged deaths related to COVID shots in children. That proposal has sent ripples of concern through the healthcare and biotech sectors, creating uncertainty for vaccine manufacturers and their investors.

The bottom line? This represents a fundamental shift in how the federal government approaches childhood immunization—from comprehensive protection to focused essentials. Whether that rebuilds public trust or creates new health risks remains to be seen, but vaccine makers are clearly bracing for impact.